Tominersen (Rg6042) For Huntington'S Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Tominersen (RG6042) is an antisense oligonucleotide (ASO) therapy developed by Roche and Ionis Pharmaceuticals for the treatment of Huntington's disease (HD). It is designed to reduce the production of the mutant huntingtin protein (mHTT) that causes the disease.[1]
Tominersen is a gapmer ASO that:
| Parameter | Value |
|---|---|
| Administration | Intrathecal injection (lumbar puncture) |
| Distribution | CSF to CNS tissue |
| Half-life in CSF | ~2-4 months |
| Metabolism | Nuclease degradation |
| Excretion | Renal |
The study of Tominersen (Rg6042) For Huntington'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Tabrizi SJ, et al. "Targeting Huntingtin Expression in Patients with Huntington's Disease." N Engl J Med. 2019. ↩︎
Liu G, et al. "Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides." Nat Biotechnol. 2018. ↩︎
Roche. "Roche provides update on tominersen programme in Huntington's disease." 2021. ↩︎
FDA. "Tominersen Briefing Document." 2021. ↩︎
Roche. "New GENERATION-HD2 trial protocol." 2023. ↩︎
Ionis Pharmaceuticals. "Tominersen Investigator's Brochure." 2020. ↩︎
Wild EJ, Tabrizi SJ. "Therapies targeting huntingtin." Handb Clin Neurol. 2023. ↩︎